145 related articles for article (PubMed ID: 30799259)
21. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
22. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
23. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
24. Axitinib-ICIs boost the RCC armamentarium.
Romero D
Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
[No Abstract] [Full Text] [Related]
25. Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
Fristrup N; Donskov F
Clin Genitourin Cancer; 2019 Aug; 17(4):254-259. PubMed ID: 31101577
[TBL] [Abstract][Full Text] [Related]
26. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
[TBL] [Abstract][Full Text] [Related]
27. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.
Dulgar O; Cil I; Zirtiloglu A; Tural D
J Oncol Pharm Pract; 2019 Sep; 25(6):1512-1515. PubMed ID: 30058939
[TBL] [Abstract][Full Text] [Related]
28. Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Miyake M
Int J Urol; 2024 Mar; 31(3):273. PubMed ID: 38173077
[No Abstract] [Full Text] [Related]
29. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
[TBL] [Abstract][Full Text] [Related]
30. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Grünwald V; Voss MH; Rini BI; Powles T; Albiges L; Giles RH; Jonasch E
Br J Cancer; 2020 Sep; 123(6):898-904. PubMed ID: 32587360
[TBL] [Abstract][Full Text] [Related]
31. Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.
Guillot A; Joly C; Barthélémy P; Meriaux E; Negrier S; Pouessel D; Chevreau C; Mahammedi H; Houede N; Roubaud G; Gravis G; Tartas S; Albiges L; Vassal C; Oriol M; Tinquaut F; Espenel S; Bouleftour W; Culine S; Fizazi K
Clin Genitourin Cancer; 2019 Feb; 17(1):e38-e43. PubMed ID: 30279115
[TBL] [Abstract][Full Text] [Related]
32. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
33. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
[No Abstract] [Full Text] [Related]
35. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
37. First-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
Li JR; Yang CK; Wang SS; Chen CS; Chiu KY; Cheng CL; Yang CR; Ho HC; Ko JL; Ou YC
Anticancer Res; 2014 Oct; 34(10):5643-7. PubMed ID: 25275068
[TBL] [Abstract][Full Text] [Related]
38. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI
BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534
[TBL] [Abstract][Full Text] [Related]
39. Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
Pradere P; Michot JM; Champiat S; Danlos FX; Marabelle A; Lambotte O; Albiges L; Le Pavec J
Eur J Cancer; 2017 Apr; 75():308-309. PubMed ID: 28259013
[No Abstract] [Full Text] [Related]
40. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma.
Yamada Y; Ohno Y; Kato Y; Kobayashi R; Hayashi H; Miyahara S; Nakane K; Mizutani K; Yokoi S; Fujii H; Iihara H; Ishihara T; Deguchi T; Sugiyama T; Suzuki A
Cancer Chemother Pharmacol; 2019 Nov; 84(5):987-992. PubMed ID: 31482225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
